CD8A and metastatic melanoma: Indeed, digital image-based approaches using immunohistochemistry24,25 or multispectral26 analysis recently demonstrated the clinical significance of spatial CD8+ T-cell evaluation in metastatic melanoma predicting response to BRAF or MAPK inhibition and correlating with improved response to immunotherapy.